[go: up one dir, main page]

RU2005117164A - CONTINUED ACTION COMPOSITIONS WITH CONTROLLED RELEASE - Google Patents

CONTINUED ACTION COMPOSITIONS WITH CONTROLLED RELEASE Download PDF

Info

Publication number
RU2005117164A
RU2005117164A RU2005117164/15A RU2005117164A RU2005117164A RU 2005117164 A RU2005117164 A RU 2005117164A RU 2005117164/15 A RU2005117164/15 A RU 2005117164/15A RU 2005117164 A RU2005117164 A RU 2005117164A RU 2005117164 A RU2005117164 A RU 2005117164A
Authority
RU
Russia
Prior art keywords
composition according
delivery
therapeutic agent
polymer
administration
Prior art date
Application number
RU2005117164/15A
Other languages
Russian (ru)
Other versions
RU2355385C2 (en
Inventor
Гуохуа ЧЕН (US)
Гуохуа ЧЕН
Пол ХЬЮСТОН (US)
Пол ХЬЮСТОН
Рой БАННИСТЕР (US)
Рой БАННИСТЕР
Тереза КАМЕДА (US)
Тереза КАМЕДА
Дэвид ПРЕБЕ (US)
Дэвид ПРЕБЕ
Лотар КЛЕЙНЕР (US)
Лотар КЛЕЙНЕР
Original Assignee
Алза Корпорейшн (Us)
Алза Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32312806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2005117164(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Алза Корпорейшн (Us), Алза Корпорейшн filed Critical Алза Корпорейшн (Us)
Publication of RU2005117164A publication Critical patent/RU2005117164A/en
Application granted granted Critical
Publication of RU2355385C2 publication Critical patent/RU2355385C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (55)

1. Инъецируемая композиция пролонгированного действия для длительной доставки лечебного средства пациенту контролируемым образом в течение предварительно определенного периода времени после введения, содержащая1. Injectable composition of prolonged action for long-term delivery of a therapeutic agent to a patient in a controlled manner for a predetermined period of time after administration, containing (a) композицию вязкого геля, включающую(a) a viscous gel composition comprising (1) биоразрушаемый, биосовместимый полимер; и(1) a biodegradable, biocompatible polymer; and (2) растворитель, имеющий растворимость в воде, меньшую или равную 7 мас.% при 25°C, в количестве, достаточном для того, чтобы пластифицировать полимер и, вследствие этого, образовать гель; и(2) a solvent having a solubility in water of less than or equal to 7 wt.% At 25 ° C, in an amount sufficient to plasticize the polymer and thereby form a gel; and (b) лечебное средство, растворенное или диспергированное в геле; где, вышеупомянутый период времени составляет от, приблизительно, двух недель до, приблизительно, двенадцати месяцев после введения.(b) a medicament dissolved or dispersed in a gel; where, the aforementioned period of time is from about two weeks to about twelve months after administration. 2. Инъецируемая композиция пролонгированного действия для длительной доставки лечебного средства пациенту контролируемым образом в течение предварительно определенного периода времени после введения, содержащая2. Injectable composition of prolonged action for prolonged delivery of a therapeutic agent to a patient in a controlled manner for a predetermined period of time after administration, containing (a) композицию вязкого геля, включающую(a) a viscous gel composition comprising (1) биоразрушаемый, биосовместимый полимер; и(1) a biodegradable, biocompatible polymer; and (2) растворитель, имеющий растворимость в воде меньшую или равную 7 мас.% при 25°C, в количестве, достаточном для того, чтобы пластифицировать полимер и, вследствие этого, образовать гель; и(2) a solvent having a solubility in water of less than or equal to 7 wt.% At 25 ° C, in an amount sufficient to plasticize the polymer and thereby form a gel; and (b) лечебное средство, растворенное или диспергированное в геле; где лечебное средство доставляется системно, контролируемым образом в течение определенного периода времени, который составляет от, приблизительно, двух недель до, приблизительно, двенадцати месяцев после введения.(b) a medicament dissolved or dispersed in a gel; where the therapeutic agent is delivered in a systematic, controlled manner over a period of time ranging from about two weeks to about twelve months after administration. 3. Инъецируемая композиция пролонгированного действия для длительной доставки лечебного средства пациенту контролируемым образом в течение предварительно определенного периода времени после введения, содержащая3. Injectable composition of prolonged action for long-term delivery of a therapeutic agent to a patient in a controlled manner for a predetermined period of time after administration, containing (a) композицию вязкого геля, включающую(a) a viscous gel composition comprising (1) биоразрушаемый, биосовместимый полимер; и(1) a biodegradable, biocompatible polymer; and (2) растворитель, имеющий растворимость в воде меньшую или равную 7 мас.% при 25°C, в количестве, достаточном для того, чтобы пластифицировать полимер и, вследствие этого, образовать гель; и(2) a solvent having a solubility in water of less than or equal to 7 wt.% At 25 ° C, in an amount sufficient to plasticize the polymer and thereby form a gel; and (b) лечебное средство, растворенное или диспергированное в геле; где лечебное средство доставляется локально, контролируемым образом в течение определенного периода времени, который составляет от, приблизительно, двух недель до, приблизительно, двенадцати месяцев после введения.(b) a medicament dissolved or dispersed in a gel; where the therapeutic agent is delivered locally, in a controlled manner, over a period of time ranging from about two weeks to about twelve months after administration. 4. Композиция по любому из пп.1-3, в которой полимер представляет собой сополимер молочной кислоты и гликолевой кислоты.4. The composition according to any one of claims 1 to 3, in which the polymer is a copolymer of lactic acid and glycolic acid. 5. Композиция по любому из пп.1-3, в которой полимер представляет собой полилактид.5. The composition according to any one of claims 1 to 3, in which the polymer is a polylactide. 6. Композиция по любому из пп.1-3, в которой полимер представляет собой полимер на основе капролактона.6. The composition according to any one of claims 1 to 3, in which the polymer is a caprolactone-based polymer. 7. Композиция по любому из пп.1-3, в которой полимер является полимером на основе молочной кислоты.7. The composition according to any one of claims 1 to 3, in which the polymer is a polymer based on lactic acid. 8. Композиция по п.4, в которой полимер имеет соотношение L/G от, приблизительно, 50:50 до, приблизительно, 100:0 и молекулярную массу, находящуюся в диапазоне от, приблизительно, 3000 до, приблизительно, 120000.8. The composition according to claim 4, in which the polymer has an L / G ratio of from about 50:50 to about 100: 0 and a molecular weight in the range of from about 3000 to about 120,000. 9. Композиция по любому из пп.1-3, содержащая от, приблизительно, 5 мас.% до, приблизительно, 90 мас.% упомянутого биоразрушаемого, биосовместимого полимера.9. The composition according to any one of claims 1 to 3, containing from about 5 wt.% To about 90 wt.% Of said biodegradable, biocompatible polymer. 10. Композиция по любому из пп.1-3, содержащая от, приблизительно, 25 мас.% до, приблизительно, 80 мас.% упомянутого биоразрушаемого, биосовместимого полимера.10. The composition according to any one of claims 1 to 3, containing from about 25 wt.% To about 80 wt.% Of said biodegradable, biocompatible polymer. 11. Композиция по любому из пп.1-3, содержащая от, приблизительно, 35 мас.% до, приблизительно, 75 мас.% упомянутого биоразрушаемого, биосовместимого полимера.11. The composition according to any one of claims 1 to 3, containing from about 35 wt.% To about 75 wt.% Of said biodegradable, biocompatible polymer. 12. Композиция по любому из пп.1-3, где упомянутый период времени составляет три месяца после введения или более.12. The composition according to any one of claims 1 to 3, where said time period is three months after administration or more. 13. Композиция по любому из пп.1-3, где упомянутый период времени составляет от, приблизительно, 3 месяцев до, приблизительно, 6 месяцев после введения.13. The composition according to any one of claims 1 to 3, where said time period is from about 3 months to about 6 months after administration. 14. Композиция по любому из пп.1-3, где упомянутый период времени составляет от, приблизительно, 3 месяцев до, приблизительно, 9 месяцев после введения.14. The composition according to any one of claims 1 to 3, where the said period of time is from about 3 months to about 9 months after administration. 15. Композиция по любому из пп.1-3, где упомянутый период времени составляет от, приблизительно, 6 месяцев до, приблизительно, 9 месяцев после введения.15. The composition according to any one of claims 1 to 3, where the said period of time is from about 6 months to about 9 months after administration. 16. Композиция по любому из пп.1-3, в которой вязкий гель дополнительно содержит полимер, выбранный из группы, состоящей из полилактидов, полигликолидов, полимеров на основе капролактона, поли(капролактона), полиангидридов, полиаминов, полиэфирамидов, полиортоэфиров, полидиоксанонов, полиацеталей, поликеталей, поликарбонатов, эфиров полифосфорных кислот, полиэфиров, полибутилентерефталата, полиортокарбонатов, полифосфазенов, сукцинатов, поли(яблочной кислоты), поли(аминокислот), поливинилпирролидона, полиэтиленгликоля, полигидроксицеллюлозы, полисахаридов, хитина, хитозана, гиалуроновой кислоты, а также сополимеров, трехкомпонентных сополимеров и смесей перечисленных соединений, и биоразрушаемых соединений и их сополимеров, включающих полимеры на основе капролактона, поликапролактоны и сополимеры, которые включают полибутилентерефталат.16. The composition according to any one of claims 1 to 3, in which the viscous gel further comprises a polymer selected from the group consisting of polylactides, polyglycolides, polymers based on caprolactone, poly (caprolactone), polyanhydrides, polyamines, polyetheramides, polyorthoesters, polydioxanones, polyacetals, polyketals, polycarbonates, polyphosphoric acid esters, polyesters, polybutylene terephthalate, polyorthocarbonates, polyphosphazenes, succinates, poly (malic acid), poly (amino acids), polyvinyl pyrrolidone, polyethylene glycol, polyhydroxycell vines, polysaccharides, chitin, chitosan, hyaluronic acid, as well as copolymers, ternary copolymers and mixtures of these compounds, and biodegradable compounds and their copolymers, including caprolactone-based polymers, polycaprolactones and copolymers that include polybutylene terephthalate. 17. Композиция по любому из пп.1-3, дополнительно включающая, по крайней мере, одно из следующих средств: порообразующее средство, регулятор растворимости для лечебного средства, осмотическое средство.17. The composition according to any one of claims 1 to 3, further comprising at least one of the following means: a pore-forming agent, a solubility regulator for a therapeutic agent, an osmotic agent. 18. Композиция по любому из пп.1-3, в которой растворитель содержит компонентный растворитель, выбранный из группы состоящей из триацетина, диацетина, трибутирина, триэтилцитрата, трибутилцитрата, ацетилтриэтилцитрата, ацетилтрибутилцитрата, триэтилглицеридов, триэтилфосфата, диэтилфталата, диэтилтартрата, минерального масла, полибутена, силиконовой жидкости, глицерина, этиленгликоля, полиэтиленгликоля, октанола, этиллактата, пропиленгликоля, пропиленкарбоната, этиленкарбоната, бутиролактона, оксида этилена, оксида пропилена, N-метил-2-пирролидона, 2-пирролидона, глицеролформаля, метилацетата, этилацетата, метилэтилкетона, диметилформамида, диметилсульфоксида, тетрагидрофурана, капролактама, децилметилсульфоксида, олеиновой кислоты и 1-додецилазацикло-гептан-2-она, а также смесей перечисленных соединений.18. The composition according to any one of claims 1 to 3, in which the solvent contains a component solvent selected from the group consisting of triacetin, diacetin, tributyrin, triethyl citrate, tributyl citrate, acetyl triethyl citrate, acetyl tributyl citrate, triethyl glyceride, triethyl phosphate, diethyl ethyl nitrate, diethyl diethylate , silicone fluid, glycerin, ethylene glycol, polyethylene glycol, octanol, ethyl lactate, propylene glycol, propylene carbonate, ethylene carbonate, butyrolactone, ethylene oxide, propylene oxide, N-methyl-2- irrolidona, 2-pyrrolidone, glycerol formal, methyl acetate, ethyl acetate, methyl ethyl ketone, dimethylformamide, dimethyl sulfoxide, tetrahydrofuran, caprolactam, decylmethylsulfoxide, oleic acid and 1-dodecylazacyclo-heptan-2-one, and mixtures thereof. 19. Композиция по любому из пп.1-3, в которой растворитель выбран из ароматического спирта, низших алкиловых и аралкиловых эфиров арилсодержащих кислот, кетонов, содержащих арил, аралкил или низший алкил, а также низших алкиловых эфиров лимонной кислоты.19. The composition according to any one of claims 1 to 3, in which the solvent is selected from aromatic alcohol, lower alkyl and aralkyl esters of aryl-containing acids, ketones containing aryl, aralkyl or lower alkyl, as well as lower alkyl citric esters. 20. Композиция по любому из пп.1-3, в которой растворитель представляет собой бензиловый спирт.20. The composition according to any one of claims 1 to 3, in which the solvent is benzyl alcohol. 21. Композиция по любому из пп.1-3, в которой растворитель представляет собой бензилбензоат.21. The composition according to any one of claims 1 to 3, in which the solvent is benzyl benzoate. 22. Композиция по любому из пп.1-3, в которой растворитель представляет собой этилбензоат.22. The composition according to any one of claims 1 to 3, in which the solvent is ethyl benzoate. 23. Композиция по любому из пп.1-3, в которой отсутствуют растворители, имеющие растворимость в воде, превышающую 7 мас.% при 25°C.23. The composition according to any one of claims 1 to 3, in which there are no solvents having a solubility in water in excess of 7 wt.% At 25 ° C. 24. Композиция по любому из пп.1-3, где упомянутая доставка представляет собой системную доставку.24. The composition according to any one of claims 1 to 3, where the aforementioned delivery is a systemic delivery. 25. Композиция по любому из пп.1-3, где упомянутая доставка представляет собой локальную доставку.25. The composition according to any one of claims 1 to 3, where the aforementioned delivery is a local delivery. 26. Композиция по любому из пп.1-3, где упомянутая доставка повторяется после определенного промежутка времени.26. The composition according to any one of claims 1 to 3, where said delivery is repeated after a certain period of time. 27. Композиция по любому из пп.1-3, обеспечивающая упомянутую доставку в множество участков.27. The composition according to any one of claims 1 to 3, providing said delivery to multiple sites. 28. Способ введения лечебного средства пациенту контролируемым образом в течение предварительно определенного периода времени после введения, включающий28. A method of administering a therapeutic agent to a patient in a controlled manner for a predetermined period of time after administration, including (i) введение пациенту(i) administration to a patient (a) композиции вязкого геля, включающей(a) a viscous gel composition comprising (1) биоразрушаемый, биосовместимый полимер; и(1) a biodegradable, biocompatible polymer; and (2) растворитель, имеющий растворимость в воде меньшую или равную 7 мас.% при 25°C, в количестве, достаточном для того, чтобы пластифицировать полимер и, вследствие этого, образовать гель; и(2) a solvent having a solubility in water of less than or equal to 7 wt.% At 25 ° C, in an amount sufficient to plasticize the polymer and thereby form a gel; and (b) лечебного средства, растворенного или диспергированного в геле; и(b) a therapeutic agent dissolved or dispersed in a gel; and (ii) доставку лечебного средства в организм пациента в течение определенного периода времени, от, приблизительно, двух недель до, приблизительно, двенадцати месяцев после введения.(ii) delivery of a therapeutic agent to a patient within a certain period of time, from about two weeks to about twelve months after administration. 29. Способ по п.28, дополнительно включающий системную доставку лечебного средства пациенту контролируемым образом.29. The method of claim 28, further comprising systemically delivering the therapeutic agent to the patient in a controlled manner. 30. Способ по п.28, дополнительно включающий повторение стадии доставки (ii) после определенного промежутка времени.30. The method according to p, further comprising repeating the stage of delivery (ii) after a certain period of time. 31. Способ по п.29, дополнительно включающий повторение стадии доставки (ii) после определенного промежутка времени.31. The method according to clause 29, further comprising repeating the stage of delivery (ii) after a certain period of time. 32. Способ по п.28, дополнительно включающий локальную доставку лечебного средства пациенту контролируемым образом.32. The method according to p, further comprising local delivery of the therapeutic agent to the patient in a controlled manner. 33. Способ по п.32, дополнительно включающий повторение стадии доставки (ii) после определенного промежутка времени.33. The method according to p, further comprising repeating the stage of delivery (ii) after a certain period of time. 34. Способ по п.32, дополнительно включающий осуществление стадии доставки (ii) в множество участков.34. The method according to p, further comprising the implementation of the stage of delivery (ii) in many areas. 35. Набор для введения для длительной доставки лечебного средства пациенту контролируемым образом в течение предварительно определенного периода времени после введения, включающий35. A kit for administration for the long-term delivery of a therapeutic agent to a patient in a controlled manner for a predetermined period of time after administration, including (a) биоразрушаемый, биосовместимый полимер;(a) a biodegradable, biocompatible polymer; (b) растворитель, имеющий растворимость в воде меньшую или равную 7 мас.% при 25°C, в количестве, достаточном для того, чтобы пластифицировать полимер и, вследствие этого, образовать гель;(b) a solvent having a solubility in water of less than or equal to 7 wt.% at 25 ° C, in an amount sufficient to plasticize the polymer and, therefore, form a gel; (с) лечебное средство, растворенное или диспергированное в геле; и, необязательно, одно или более средств из числа следующих:(c) a therapeutic agent dissolved or dispersed in a gel; and, optionally, one or more of the following: (d) эмульгирующее средство;(d) an emulsifying agent; (e) порообразующее средство;(e) a pore-forming agent; (f) регулятор растворимости лечебного средства, необязательно связанный с лечебным средством; и(f) a solubility regulator of the therapeutic agent, optionally associated with the therapeutic agent; and (g) осмотическое средство;(g) an osmotic agent; где, по крайней мере, лечебное средство, необязательно связанное с регулятором растворимости, сохраняется отдельно от растворителя вплоть до времени введения лечебного средства пациенту.where, at least, the therapeutic agent, optionally associated with a solubility regulator, is stored separately from the solvent until the time of administration of the therapeutic agent to the patient. 36. Композиция по п.1, где композиция вязкого геля содержит смесь биоразрушаемых, биосовместимых полимеров.36. The composition according to claim 1, where the composition of a viscous gel contains a mixture of biodegradable, biocompatible polymers. 37. Композиция по п.36, в которой смесь полимеров включает сополимер молочной кислоты и гликолевой кислоты.37. The composition according to clause 36, in which the polymer mixture comprises a copolymer of lactic acid and glycolic acid. 38. Композиция по п.36, в которой смесь полимеров включает полилактид.38. The composition according to clause 36, in which the polymer mixture comprises polylactide. 39. Композиция по п.36, в которой смесь полимеров включает полимер на основе капролактона.39. The composition according to clause 36, in which the polymer mixture comprises a caprolactone-based polymer. 40. Композиция по п.36, в которой смесь полимеров включает полимер, имеющий соотношение L/G от, приблизительно, 50:50 до, приблизительно, 100:0 и молекулярную массу, находящуюся в диапазоне от, приблизительно, 3000 до, приблизительно, 120000.40. The composition according to clause 36, in which the polymer mixture comprises a polymer having an L / G ratio of from about 50:50 to about 100: 0 and a molecular weight in the range of from about 3000 to about 120,000. 41. Композиция по п.36, содержащая от, приблизительно, 5 мас.% до, приблизительно, 90 мас.% упомянутого биоразрушаемого, биосовместимого полимера.41. The composition according to clause 36, containing from about 5 wt.% To about 90 wt.% Of the aforementioned biodegradable, biocompatible polymer. 42. Композиция по п.41, содержащая от, приблизительно, 25 мас.% до, приблизительно, 80 мас.% упомянутого биоразрушаемого, биосовместимого полимера.42. The composition according to paragraph 41, containing from about 25 wt.% To about 80 wt.% Of said biodegradable, biocompatible polymer. 43. Композиция по п.41, содержащая от, приблизительно, 35 мас.% до, приблизительно, 75 мас.% упомянутого биоразрушаемого, биосовместимого полимера.43. The composition according to paragraph 41, containing from about 35 wt.% To about 75 wt.% Of said biodegradable, biocompatible polymer. 44. Композиция по п.36, где упомянутая доставка представляет собой системную доставку.44. The composition of claim 36, wherein said delivery is a system delivery. 45. Композиция по п.36, где упомянутая доставка представляет собой локальную доставку.45. The composition of claim 36, wherein said delivery is local delivery. 46. Композиция по п.36, где упомянутая доставка повторяется после определенного промежутка времени.46. The composition according to clause 36, where the aforementioned delivery is repeated after a certain period of time. 47. Композиция по п.36, обеспечивающая упомянутую доставку в множество участков.47. The composition according to clause 36, providing the aforementioned delivery to many sites. 48. Способ введения лечебного средства пациенту контролируемым образом в течение предварительно определенного периода времени после введения, включающий48. A method for administering a therapeutic agent to a patient in a controlled manner for a predetermined period of time after administration, including (i) введение пациенту(i) administration to a patient (a) композиции вязкого геля, включающей(a) a viscous gel composition comprising (1) смесь биоразрушаемых, биосовместимых полимеров; и(1) a mixture of biodegradable, biocompatible polymers; and (2) растворитель, имеющий растворимость в воде, меньшую или равную 7 мас.% при 25°C, в количестве, достаточном для того, чтобы пластифицировать полимер и, вследствие этого, образовать гель; и(2) a solvent having a solubility in water of less than or equal to 7 wt.% At 25 ° C, in an amount sufficient to plasticize the polymer and thereby form a gel; and (b) лечебного средства, растворенного или диспергированного в геле; и(b) a therapeutic agent dissolved or dispersed in a gel; and (ii) доставку лечебного средства в организм пациента в течение определенного периода времени, от, приблизительно, двух недель до, приблизительно, двенадцати месяцев после введения.(ii) delivery of a therapeutic agent to a patient within a certain period of time, from about two weeks to about twelve months after administration. 49. Способ по п.48, дополнительно включающий системную доставку лечебного средства пациенту контролируемым образом.49. The method of claim 48, further comprising systemically delivering the therapeutic agent to the patient in a controlled manner. 50. Способ по п.48, дополнительно включающий повторение стадии доставки (ii) после определенного промежутка времени.50. The method of claim 48, further comprising repeating the delivery step (ii) after a certain period of time. 51. Способ по п.49, дополнительно включающий повторение стадии доставки (ii) после определенного промежутка времени.51. The method according to 49, further comprising repeating the stage of delivery (ii) after a certain period of time. 52. Способ по п.48, дополнительно включающий локальную доставку лечебного средства пациенту контролируемым образом.52. The method of claim 48, further comprising local delivery of the therapeutic agent to the patient in a controlled manner. 53. Способ по п.52, дополнительно включающий повторение стадии доставки (ii) после определенного периода времени.53. The method according to paragraph 52, further comprising repeating the stage of delivery (ii) after a certain period of time. 54. Способ по п.52, дополнительно включающий осуществление стадии доставки в множество участков.54. The method according to paragraph 52, further comprising the implementation of the stage of delivery to many sites. 55. Набор для введения для длительной доставки лечебного средства пациенту контролируемым образом в течение предварительно определенного периода времени после введения, включающий 55. An administration kit for the long-term delivery of a therapeutic agent to a patient in a controlled manner for a predetermined period of time after administration, including (a) смесь биоразрушаемых, биосовместимых полимеров;(a) a mixture of biodegradable, biocompatible polymers; (b) растворитель, имеющий растворимость в воде меньшую или равную 7 мас.% при 25°C, в количестве, достаточном для того, чтобы пластифицировать полимер и, вследствие этого, образовать гель;(b) a solvent having a solubility in water of less than or equal to 7 wt.% at 25 ° C, in an amount sufficient to plasticize the polymer and, therefore, form a gel; (с) лечебное средство, растворенное или диспергированное в геле; и, необязательно, одно или более средств из числа следующих:(c) a therapeutic agent dissolved or dispersed in a gel; and, optionally, one or more of the following: (d) эмульгирующее средство;(d) an emulsifying agent; (e) порообразующее средство;(e) a pore-forming agent; (f) регулятор растворимости лечебного средства, необязательно связанный с лечебным средством; и(f) a solubility regulator of the therapeutic agent, optionally associated with the therapeutic agent; and (g) осмотическое средство;(g) an osmotic agent; где, по крайней мере, лечебное средство, необязательно объединенное с регулятором растворимости, сохраняется отдельно от растворителя вплоть до времени введения лечебного средства пациенту.where, at least, the therapeutic agent, optionally combined with a solubility regulator, is stored separately from the solvent until the time of administration of the therapeutic agent to the patient.
RU2005117164/15A 2002-11-06 2003-11-04 Compositions of prolongedaction with controlled release RU2355385C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42442802P 2002-11-06 2002-11-06
US60/424,428 2002-11-06

Publications (2)

Publication Number Publication Date
RU2005117164A true RU2005117164A (en) 2006-01-20
RU2355385C2 RU2355385C2 (en) 2009-05-20

Family

ID=32312806

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005117164/15A RU2355385C2 (en) 2002-11-06 2003-11-04 Compositions of prolongedaction with controlled release

Country Status (25)

Country Link
US (1) US7368126B2 (en)
EP (1) EP1581181B1 (en)
JP (1) JP2006508127A (en)
KR (1) KR20050088288A (en)
CN (1) CN1713890A (en)
AR (1) AR041913A1 (en)
AT (1) ATE418323T1 (en)
AU (1) AU2003295409B2 (en)
BR (1) BR0315304A (en)
CA (1) CA2504608C (en)
CL (1) CL2003002277A1 (en)
DE (1) DE60325511D1 (en)
EC (2) ECSP055838A (en)
MA (1) MA27523A1 (en)
MX (1) MXPA05004927A (en)
MY (1) MY140155A (en)
NO (1) NO20052635L (en)
NZ (1) NZ539810A (en)
PE (1) PE20040675A1 (en)
PL (1) PL377333A1 (en)
RU (1) RU2355385C2 (en)
TW (1) TW200503774A (en)
UY (1) UY28067A1 (en)
WO (1) WO2004043432A2 (en)
ZA (1) ZA200504529B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009031919A1 (en) * 2007-09-05 2009-03-12 Ruslan Dmitrievich Ilyuk Alcoholism recurrence preventing agent and method for the use thereof

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US20060280774A1 (en) * 1995-06-02 2006-12-14 Allergan, Inc. Compositions and methods for treating glaucoma
WO2001036000A1 (en) * 1999-11-15 2001-05-25 Bio Syntech Canada, Inc. Temperature-controlled and ph-dependant self-gelling biopolymeric aqueous solution
US20030158302A1 (en) * 1999-12-09 2003-08-21 Cyric Chaput Mineral-polymer hybrid composition
EP1237585B1 (en) * 1999-12-09 2003-06-18 Biosyntech Canada Inc. Mineral-polymer hybrid composition
US20050042194A1 (en) * 2000-05-11 2005-02-24 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
AU2001268882B2 (en) * 2000-06-29 2006-07-06 Smith & Nephew Orthopaedics Ag Composition and method for the repair and regeneration of cartilage and other tissues
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
DE60125973D1 (en) * 2000-11-15 2007-02-22 Biosyntech Canada Inc METHOD FOR RECOVERING A DAMAGED BAND DISC
AU3649502A (en) 2000-11-29 2002-06-11 Oculex Pharm Inc Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
JP2005519873A (en) * 2001-11-14 2005-07-07 アルザ・コーポレーション Catheter injectable depot compositions and their use
US20070196415A1 (en) * 2002-11-14 2007-08-23 Guohua Chen Depot compositions with multiple drug release rate controls and uses thereof
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
DE60325742D1 (en) 2002-07-31 2009-02-26 Alza Corp INJECTABLE MULTIMODAL POLYMERS DEPOT COMPOSITIONS AND THEIR USES
MXPA05001242A (en) * 2002-07-31 2005-06-08 Alza Corp Injectable depot compositions and uses thereof.
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
MXPA05010604A (en) * 2003-03-31 2005-11-23 Alza Corp Osmotic delivery system and method for decreasing start-up times for osmotic delivery systems.
CL2004000698A1 (en) * 2003-03-31 2005-05-20 Alza Corp NON-WATERPROOF PHARMACEUTICAL COMPOSITION THAT INCLUDES AT LEAST AN ACTIVE INGREDIENT AND A UNIQUE PHASE VEHICLE CONTAINING AT LEAST A POLYMER AND AT LEAST A SOLVENT, BEING THE MISCIBLE VEHICLE IN WATER; PROCEDURE FOR PREPARATION; DEVICE D
BRPI0408862A (en) * 2003-03-31 2006-04-11 Alza Corp osmotic pump with internal pressure dissipating device
KR20060023140A (en) * 2003-05-30 2006-03-13 알자 코포레이션 Implantable Elastomer Depot Compositions, Uses thereof, and Methods of Making the Same
US20070184084A1 (en) * 2003-05-30 2007-08-09 Guohua Chen Implantable elastomeric caprolactone depot compositions and uses thereof
US20050106214A1 (en) * 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
WO2005107708A1 (en) 2004-04-30 2005-11-17 Allergan, Inc. Biodegradable intravitreal tyrosine kinase inhibitors implants
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8529927B2 (en) * 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US20050266087A1 (en) * 2004-05-25 2005-12-01 Gunjan Junnarkar Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
WO2006078320A2 (en) 2004-08-04 2006-07-27 Brookwood Pharmaceuticals, Inc. Methods for manufacturing delivery devices and devices thereof
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US8541413B2 (en) * 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
US9993558B2 (en) 2004-10-01 2018-06-12 Ramscor, Inc. Sustained release eye drop formulations
NZ554426A (en) * 2004-10-01 2010-05-28 Ramscor Inc Conveniently implantable sustained release drug compositions comprising at least one non-polymeric excipient
AR052155A1 (en) * 2004-12-14 2007-03-07 Novartis Ag ORGANIC COMPOUNDS
CA2590696A1 (en) * 2004-12-15 2006-06-22 Qlt Usa, Inc. Sustained delivery formulations of octreotide compounds
US20060141040A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
EP1871348A4 (en) * 2005-03-01 2012-08-01 Sun Pharma Advanced Res Co Ltd Sustained release pharmaceutical compositions
KR20080031394A (en) * 2005-07-12 2008-04-08 리노보 리미티드 Pharmaceutical composition comprising TVF-beta superfamily member
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US20090075383A1 (en) * 2005-11-04 2009-03-19 Bio Syntech Canada Inc. Composition and method for efficient delivery of nucleic acids to cells using chitosan
JP5153340B2 (en) * 2005-11-16 2013-02-27 学校法人東海大学 Drug release control composition and drug release medical device
KR101245919B1 (en) * 2005-12-22 2013-03-20 노파르티스 아게 Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers
US8236904B2 (en) 2005-12-28 2012-08-07 Ethicon, Inc. Bioabsorbable polymer compositions exhibiting enhanced crystallization and hydrolysis rates
US20070149640A1 (en) * 2005-12-28 2007-06-28 Sasa Andjelic Bioabsorbable polymer compositions exhibiting enhanced crystallization and hydrolysis rates
US20070178138A1 (en) * 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
WO2007140416A2 (en) 2006-05-30 2007-12-06 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US8802128B2 (en) * 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20070298073A1 (en) * 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
JP5048773B2 (en) 2006-08-09 2012-10-17 インターシア セラピューティクス，インコーポレイティド Osmotic delivery system and piston assembly
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8846073B2 (en) * 2006-12-19 2014-09-30 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
NZ580447A (en) 2007-04-23 2011-06-30 Intarcia Therapeutics Inc Suspension formulations of insulinotropic peptides and uses thereof
US20080287464A1 (en) 2007-05-18 2008-11-20 Wright Jeremy C Depot Formulations
JP2010531807A (en) 2007-05-25 2010-09-30 トルマー セラピューティクス， インコーポレイテッド Slow-broadcast formulation of risperidone compound
WO2008149364A2 (en) * 2007-06-07 2008-12-11 Sarah Brenner Methods for diagnosing hypersensitivity reactions
WO2009015197A1 (en) * 2007-07-24 2009-01-29 University Of Memphis Research Foundation Local delivery method and composition
US8470360B2 (en) 2008-04-18 2013-06-25 Warsaw Orthopedic, Inc. Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
US9090737B2 (en) * 2007-11-13 2015-07-28 Surmodics, Inc. Viscous terpolymers as drug delivery platform
JP5502751B2 (en) 2007-12-20 2014-05-28 エボニック コーポレイション Process for preparing microparticles with low residual solvent concentration
AU2013201877B2 (en) * 2008-01-30 2015-01-29 Novartis Ag Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
RU2541104C2 (en) 2008-01-30 2015-02-10 Новартис Аг Prolonged release formulation containing octreotide and three linear polymers of poly(lactide-co-glycolic acid)
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US8956641B2 (en) * 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of inflammatory diseases
US8883768B2 (en) * 2008-04-18 2014-11-11 Warsaw Orthopedic, Inc. Fluocinolone implants to protect against undesirable bone and cartilage destruction
US9072727B2 (en) * 2008-04-18 2015-07-07 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of degenerative disc disease
US8889173B2 (en) * 2008-04-18 2014-11-18 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
US20090263456A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Methods and Compositions for Reducing Preventing and Treating Adhesives
US8846068B2 (en) * 2008-04-18 2014-09-30 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising a local anesthetic
US8524267B2 (en) * 2008-04-18 2013-09-03 Warsaw Orthopedic, Inc. Dexamethasone formulations in a biodegradable material
US7993666B2 (en) * 2008-04-18 2011-08-09 Warsaw Orthopedic, Inc. Methods and compositions for treating pain comprising a statin
US8846770B2 (en) * 2008-06-18 2014-09-30 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
DK2341905T4 (en) * 2008-09-04 2023-12-11 Amylin Pharmaceuticals Llc DEPOT FORMULATIONS WITH NON-AQUEOUS CARRIERS
US9623222B2 (en) * 2008-10-30 2017-04-18 Warsaw Orthopedic, Inc. Drug depot with anchor
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
AR074603A1 (en) * 2008-12-15 2011-01-26 Novartis Ag FORMULATION OF OCTREOTIDE DEPOSIT WITH EXPOSURE LEVELS CONSTANTLY HIGH. METHOD. KIT
US8951546B2 (en) 2008-12-23 2015-02-10 Surmodics Pharmaceuticals, Inc. Flexible implantable composites and implants comprising same
US20100158978A1 (en) * 2008-12-23 2010-06-24 Peter Markland Bioactive spray coating compositions and methods of making and uses thereof
US8974808B2 (en) * 2008-12-23 2015-03-10 Surmodics, Inc. Elastic implantable composites and implants comprising same
US9415197B2 (en) 2008-12-23 2016-08-16 Surmodics, Inc. Implantable suction cup composites and implants comprising same
US20100168807A1 (en) * 2008-12-23 2010-07-01 Burton Kevin W Bioactive terpolymer compositions and methods of making and using same
US20100228097A1 (en) * 2009-03-04 2010-09-09 Warsaw Orthopedic, Inc. Methods and compositions to diagnose pain
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
US20120172456A1 (en) * 2009-09-10 2012-07-05 Little Steven R Engineered microparticles for macromolecule delivery
RU2753280C2 (en) 2009-09-28 2021-08-12 Интарсия Терапьютикс, Инк. Rapid accomplishment and/or termination of substantial stable drug delivery
US20110097380A1 (en) * 2009-10-28 2011-04-28 Warsaw Orthopedic, Inc. Clonidine formulations having antimicrobial properties
BR112012010983A2 (en) 2009-11-09 2016-04-12 Allergan Inc compositions and methods for hair growth stimulation
US9993441B2 (en) 2009-12-30 2018-06-12 Surmodics, Inc. Controlled release matrix barrier structure for subcutaneous medical devices
JP5809169B2 (en) 2010-01-22 2015-11-10 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ Therapeutic drug sustained release intraluminal implant
WO2011133370A1 (en) * 2010-04-23 2011-10-27 Medtronic, Inc. Shelf stable pharmaceutical depot
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
GB2481018B (en) * 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
JP5976651B2 (en) 2010-08-30 2016-08-24 サーモディクス ファーマシューティカルズ， インコーポレイテッド Biodegradable terpolymers and terpolymer blends as pressure sensitive adhesives
WO2012034079A2 (en) * 2010-09-09 2012-03-15 Micell Technologies, Inc. Macrolide dosage forms
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2012125914A1 (en) * 2011-03-16 2012-09-20 University Of Delaware Injectable delivery system for heparan sulfate binding growth factors
CN102133180B (en) * 2011-03-18 2016-03-09 黄芳 A kind of long-acting injection preparation of sterides 5 alpha-reductase inhibitor and preparation method thereof
US9005634B2 (en) 2011-04-13 2015-04-14 Medtronic, Inc. Shelf stable pharmaceutical depot
US9446135B2 (en) * 2011-04-25 2016-09-20 Shandong Luye Pharmaceutical Co., Ltd. Risperidone sustained release microsphere composition
US8951996B2 (en) * 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
NZ722096A (en) 2011-12-15 2016-11-25 Alkermes Pharma Ireland Ltd Prodrugs of secondary amine compounds
WO2013162270A1 (en) * 2012-04-24 2013-10-31 서울대학교산학협력단 Breast prosthesis allowing controlled release of drug and production method for same
US8822423B2 (en) * 2012-05-17 2014-09-02 Janssen Biotech, Inc. Affinity peptides toward infliximab
US10653621B2 (en) 2012-09-27 2020-05-19 Allergan, Inc. Biodegradable drug delivery systems for the sustained release of proteins
CN109602691A (en) 2013-02-15 2019-04-12 阿勒根公司 Sustained drug delivery implantation material
CN105163719B (en) 2013-03-11 2019-03-08 度瑞公司 Injectable Controlled Release Compositions Containing High Viscosity Liquid Carriers
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
KR102370470B1 (en) 2013-03-15 2022-03-04 헤론 테라퓨틱스 인코포레이티드 Compositions of a polyorthoester and an aprotic solvent
CA2926515C (en) 2013-10-31 2020-11-24 Allergan, Inc. Prostamide-containing intraocular implants and methods of use thereof
CN105764491A (en) 2013-12-09 2016-07-13 度瑞公司 Pharmaceutically active agent complexes, polymer complexes, and compositions and methods comprising the same
RU2684611C2 (en) * 2013-12-31 2019-04-10 ПБ энд Б СА Compositions for controlled release of fatty acids for use in reconstructing and correcting body-shaping
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
SG11201703632WA (en) 2014-11-07 2017-06-29 Indivior Uk Ltd Buprenorphine dosing regimens
ES2968262T3 (en) 2015-06-03 2024-05-08 I2O Therapeutics Inc Implant placement systems
EP3324890A4 (en) * 2015-07-23 2019-06-19 Allergan, Inc. TREATMENT OF OCULAR GLAUCOMA THROUGH INTRACAMERULAR IMPLANTS
CN109310743A (en) 2016-05-16 2019-02-05 因塔西亚制药公司 Glucagon receptor selective polypeptides and methods of using the same
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
BR112018077259A2 (en) 2016-06-30 2019-06-18 Durect Corporation depot formulations
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
MX2019008006A (en) 2017-01-03 2019-08-29 Intarcia Therapeutics Inc METHODS INCLUDING THE CONTINUOUS ADMINISTRATION OF A GLP-1 RECEPTOR AGONIST AND THE CO-ADMINISTRATION OF A DRUG.
EP3638311A4 (en) 2017-06-13 2020-12-16 The University of British Columbia POLYMERIC PASTE COMPOSITIONS FOR ACTIVE SUBSTANCE RELEASE
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
CN119185557A (en) 2018-04-06 2024-12-27 阿玛治疗公司 Compositions for controlled release of therapeutic agents
CN109898236B (en) * 2019-03-15 2021-12-14 深圳市光远生物材料有限责任公司 Drug-loaded nanofiber membrane and preparation method and application thereof
CN115666621A (en) 2020-01-13 2023-01-31 度勒科特公司 Sustained release drug delivery system with reduced impurities and related methods
CN111548482B (en) * 2020-04-02 2022-09-13 复旦大学 Nitric oxide donor modified copolymer, sustained-release preparation containing nitric oxide donor modified copolymer, and preparation method and application of nitric oxide donor modified copolymer
CA3203561A1 (en) 2021-01-12 2022-07-21 Adrian Neil Verity Sustained release drug delivery systems and related methods
WO2023278695A1 (en) * 2021-06-30 2023-01-05 The University Of North Carolina At Chapel Hill Injectable, biodegradable and removable polymer based drug suspension for ultra-long-acting drug delivery
CN116270491A (en) * 2023-03-30 2023-06-23 北京博恩特药业有限公司 Leuprolide acetate sustained-release microsphere and preparation method thereof

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797492A (en) 1972-12-27 1974-03-19 Alza Corp Device for dispensing product with directional guidance member
US3887790A (en) * 1974-10-07 1975-06-03 Vernon H Ferguson Wrap-around electric resistance heater
US3987790A (en) 1975-10-01 1976-10-26 Alza Corporation Osmotically driven fluid dispenser
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
JPS5933320B2 (en) * 1981-04-03 1984-08-15 株式会社東芝 optical information recording medium
US4443340A (en) 1981-10-09 1984-04-17 Betz Laboratories, Inc. Control of iron induced fouling in water systems
US4985404A (en) 1984-10-04 1991-01-15 Monsanto Company Prolonged release of biologically active polypeptides
US4865845A (en) 1986-03-21 1989-09-12 Alza Corporation Release rate adjustment of osmotic or diffusional delivery devices
US4853218A (en) 1987-02-24 1989-08-01 Schering Corporation Zinc-protamine-alpha interferon complex
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5085866A (en) 1988-12-02 1992-02-04 Southern Research Institute Method of producing zero-order controlled-released devices
US5057318A (en) 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5059423A (en) 1988-12-13 1991-10-22 Alza Corporation Delivery system comprising biocompatible beneficial agent formulation
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5112614A (en) 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
US5234693A (en) 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5234692A (en) 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5151093A (en) 1990-10-29 1992-09-29 Alza Corporation Osmotically driven syringe with programmable agent delivery
US5620700A (en) 1990-10-30 1997-04-15 Alza Corporation Injectable drug delivery system and method
GB9027422D0 (en) 1990-12-18 1991-02-06 Scras Osmotically driven infusion device
US5137727A (en) 1991-06-12 1992-08-11 Alza Corporation Delivery device providing beneficial agent stability
US5288214A (en) 1991-09-30 1994-02-22 Toshio Fukuda Micropump
FI933471L (en) 1991-12-19 1993-08-05 Mitsui Toatsu Chemicals POLYHYDROXYCARBOXYL ACID OCH FOERFARANDE FOER DESS FRAMSTAELLNING
US5209746A (en) 1992-02-18 1993-05-11 Alza Corporation Osmotically driven delivery devices with pulsatile effect
US5456679A (en) 1992-02-18 1995-10-10 Alza Corporation Delivery devices with pulsatile effect
US5308348A (en) 1992-02-18 1994-05-03 Alza Corporation Delivery devices with pulsatile effect
US5656297A (en) 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
GB9211268D0 (en) 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US5242910A (en) 1992-10-13 1993-09-07 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
EP1013270A3 (en) 1992-12-02 2001-03-28 Alkermes Controlled Therapeutics, Inc. Controlled release growth hormone containing microspheres
US5468253A (en) 1993-01-21 1995-11-21 Ethicon, Inc. Elastomeric medical device
EP2283821A1 (en) 1993-11-19 2011-02-16 Alkermes, Inc. Preparation of biodegradable microparticles containing a biologically active agent
US5556905A (en) 1994-03-30 1996-09-17 Reilly Industries, Inc. Physically-modified degradable thermoplastic compositions
EP1125577B1 (en) 1994-04-08 2006-02-15 QLT USA, Inc. Liquid drug delivery compositions
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
UA10911C2 (en) * 1994-08-10 1996-12-25 Мале Впроваджувальне Підприємство "Іhтерфалл" BIOSMIX HYDROGEL
US5639851A (en) 1995-10-02 1997-06-17 Ethicon, Inc. High strength, melt processable, lactide-rich, poly(lactide-CO-P-dioxanone) copolymers
US6113624A (en) 1995-10-02 2000-09-05 Ethicon, Inc. Absorbable elastomeric polymer
CA2275587C (en) 1996-12-20 2006-10-24 Alza Corporation Injectable depot gel composition and method of preparing the composition
US6193991B1 (en) 1997-10-29 2001-02-27 Atul J. Shukla Biodegradable delivery systems of biologically active substances
CN100370967C (en) * 1999-06-04 2008-02-27 阿尔萨公司 Embedding gel composition and preparation method thereof
WO2002000137A1 (en) 2000-06-28 2002-01-03 Shukla Atul J Biodegradable vehicles and delivery systems of biologically active substances
WO2002038185A2 (en) * 2000-11-13 2002-05-16 Atrix Laboratories, Inc. Injectable sustained release delivery system with loperamide
EP1363602A4 (en) 2001-01-25 2006-01-11 Euro Celtique Sa Local anesthetic, and method of use
IL157531A0 (en) 2001-02-23 2004-03-28 Genentech Inc Erodible polymers for injection
JP2005519873A (en) 2001-11-14 2005-07-07 アルザ・コーポレーション Catheter injectable depot compositions and their use
CA2466642C (en) 2001-11-14 2011-01-18 Guohua Chen Injectable depot composition
WO2003041684A2 (en) 2001-11-14 2003-05-22 Alza Corporation Injectable depot compositions and uses thereof
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
TWI353854B (en) 2002-06-25 2011-12-11 Alza Corp Short duration depot formulations
DE60325742D1 (en) 2002-07-31 2009-02-26 Alza Corp INJECTABLE MULTIMODAL POLYMERS DEPOT COMPOSITIONS AND THEIR USES
MXPA05001242A (en) 2002-07-31 2005-06-08 Alza Corp Injectable depot compositions and uses thereof.
US20050106214A1 (en) 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
US20050281879A1 (en) 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009031919A1 (en) * 2007-09-05 2009-03-12 Ruslan Dmitrievich Ilyuk Alcoholism recurrence preventing agent and method for the use thereof

Also Published As

Publication number Publication date
CA2504608A1 (en) 2004-05-27
MA27523A1 (en) 2005-09-01
DE60325511D1 (en) 2009-02-05
NO20052635L (en) 2005-07-20
PL377333A1 (en) 2006-01-23
WO2004043432A3 (en) 2004-07-08
AU2003295409B2 (en) 2010-02-11
ZA200504529B (en) 2006-08-30
NO20052635D0 (en) 2005-06-01
RU2355385C2 (en) 2009-05-20
HK1085387A1 (en) 2006-08-25
KR20050088288A (en) 2005-09-05
AR041913A1 (en) 2005-06-01
MY140155A (en) 2009-11-30
AU2003295409A1 (en) 2004-06-03
CL2003002277A1 (en) 2005-05-06
US7368126B2 (en) 2008-05-06
JP2006508127A (en) 2006-03-09
CN1713890A (en) 2005-12-28
ATE418323T1 (en) 2009-01-15
EP1581181B1 (en) 2008-12-24
EP1581181A2 (en) 2005-10-05
CA2504608C (en) 2013-01-08
ECSP055838A (en) 2005-09-20
TW200503774A (en) 2005-02-01
WO2004043432A2 (en) 2004-05-27
NZ539810A (en) 2008-03-28
BR0315304A (en) 2005-08-16
MXPA05004927A (en) 2005-09-08
PE20040675A1 (en) 2004-09-25
US20040151753A1 (en) 2004-08-05
UY28067A1 (en) 2003-12-31
ECSP056249A (en) 2006-10-17

Similar Documents

Publication Publication Date Title
RU2005117164A (en) CONTINUED ACTION COMPOSITIONS WITH CONTROLLED RELEASE
RU2006101985A (en) DOSED FORMES OF ANESTHESIC PRODUCTS WITH LONG-TERM RELEASE FOR ANALGESIS
CA2787097C (en) Low viscosity liquid polymeric delivery system
WO2005009408B1 (en) Sustained release dosage forms of anesthetics for pain management
JP2006508127A5 (en)
Parent et al. PLGA in situ implants formed by phase inversion: Critical physicochemical parameters to modulate drug release
RU2207350C2 (en) Biodegradable polymers with phosphate-prolonged chains, compositions, products, methods of manufacture and use thereof
CA2275525A1 (en) Gel composition and methods
US6193991B1 (en) Biodegradable delivery systems of biologically active substances
CN103491946B (en) Biodegradable drug delivery compositions
US7560120B2 (en) Vehicles for delivery of biologically active substances
KR101865689B1 (en) Injectable Flowable Composition Comprising Buprenorphine
JP2021138773A (en) Delivery system, amide type topical anesthetic and pharmaceutical composition including meloxicam
US10592168B1 (en) Injectable flowable composition comprising buprenorphine
US20040109893A1 (en) Sustained release dosage forms of anesthetics for pain management
KR930007454A (en) Polymerizable Compositions Useful as Controlled Release Implants
JP2001508756A (en) Non-polymer sustained dissociation delivery system
Loh et al. Biodegradable thermogelling polymers
RU2006146610A (en) PHARMACEUTICAL COMPOSITIONS, INCLUDING POLYETHYLENE GLYCOL, POSSESSING MOLECULAR MASS, EQUAL LESS THAN 600 DALTON
JP2018522906A5 (en)
CN102112107A (en) Controlled release copolymer formulation with improved release kinetics
HRP20201991T1 (en) LIQUID POLYMER DELIVERY SYSTEM FOR EXTENDED DRUG ADMINISTRATION
RU2320321C2 (en) Depot compositions of shot-term action
EP2983663B1 (en) Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction
CN1332016A (en) Biodegradable Carriers and Biodegradable Delivery Systems